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Sulfation and Glucuronidation as
Competing Pathways in the Metabolism
of Hydroxamic Acids:
The Role of N,O*Sulfonation in Chemical
Carcinogenesis of Aromatic Amines
by Gerard J. Mulder* and John H. N. Meerman*
Aromatic amines can be metabolized by N-acetylation and N-hydroxylation to hydroxamic acids;
these subsequently are conjugated to form the N,O-sulfonate and N,O-glucuronide conjugates. The
N,O-sulfonates are highly labile metabolites that generate reactive intermediates involved in the co-
valent binding of the parent compound to protein, RNA and DNA, as well as to low molecular com-
pounds like glutathione. This paper discusses methods used to decrease sulfation in vivo, and there-
by to enhance the formation of the more stable N,O-glucuronides from N-hydroxy-2-acetylamino-
fluorene and N-hydroxy-4-acetylamino-4'-fluorobiphenyl. Acetaminophen pretreatment decreases
the sulfate availability, but results in many side effects that complicate the analysis of the results.
An 8% casein diet reduces the sulfate availability in the rat to approximately 20% of control and
thus offers an effective approach to decrease sulfation.
The most effective selective inhibition of sulfation is by pentachlorophenol, which very strongly
reducesN,O-sulfonation of both hydroxamic acids, and selectively inhibits the formation of DNA ad-
ducts that have retained the N-acetyl group. This inhibitor and the related 2,6-dichloro-4-nitro-
phenol can be employed to study the role of sulfation of hydroxamic acids in initiation and promo-
tion of tumor formation by aromatic amines.
Introduction
An important pathway in the conversion of
aromatic amines to ultimate carcinogenic metabo-
lites is N-acetylation followed by N-hydroxylation to
form the hydroxamic acid derivatives; these, subse-
quently, are substrates for conjugation (1, 2). The
main products are the relatively stable glucuronides
and the more labile sulfate conjugates of the N-hy-
droxy group (2-4). Since the spontaneous breakdown
of the N,O-glucuronides is much slower than that of
the N,O-sulfonates, the chemical mechanisms of
breakdown of these conjugates can more easily be
studied with the N,O-glucuronides. Of course, it has
to be kept in mind that the mechanisms may be dif-
ferent for the various conjugates. The sulfate conju-
gates are very prone to rapid, spontaneous rear-
rangements and, in general, are very labile in aque-
ous media, even at pH 7 (2, 5). However, the more
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stable glucuronide conjugate of N-hydroxy-2-acetyl-
aminofluorene W-hydroxy-2-AAF) can be isolated,
and the properties of the reactive intermediate
formed during its breakdown have been studied in
vitro (2, 3). Similarly, the breakdown products of the
glucuronide conjugate of N-hydroxyphenacetin
could be characterized completely (5). Other rele-
vant reactions that have been studied extensively,
especially with N-hydroxy-2-AAF, are transacety-
lation, acetylation and deacetylation (6, 7). In ad-
dition, the N,O-glucuronide of N-hydroxy-2-AAF
may be attacked by microsomal deacetylases which
results in the formation of a reactive N,O-glucuro-
nide ofN-hydroxy-2-aminofluorene (8).
The sulfate conjugates of various hydroxamic
acids have been implicated in carcinogenesis by
those compounds (4). Early evidence came from
work of the group of De Baun and the Millers (9, 10)
and ofKing and Phillips (11). However, it has turned
out to be rather difficult to prove unambiguously a
role of sulfation in the carcinogenesis byN-hydroxy-
2-AAF, because other very reactive metabolites ofMULDER AND MEERMAN
this hydroxamic acid might be ultimate carcinogens
(12). One of the main reasons is probably that no
highly selective inhibitors of sulfation and/or glucu-
ronidation were available to evaluate the role of
these conjugations in carcinogenesis by aromatic
amines or hydroxamic acids. In this paper we want
to review the available methods to change, more or
less specifically, the balance between glucuroni-
dation and sulfation. This can be done either at the
level of sulfate availability (by dietary methods or
nonselective drugs) or at the level of the conjugat-
ing enzymes through selective inhibition of sulfation
by pentachlorophenol (PCP) and 2,6-dichloro-4-nitro-
phenol (DCNP).
It seems relatively easy to study the involvement
of glucuronides in the carcinogenicity of a com-
pound, because usually the glucuronides can be
isolated and subsequently tested in vivo. Thus, the
role of the N-glucuronide of N-hydroxy-2-naphthyl-
amine in bladder carcinogenesis (13) can be evalu-
ated directly. However, if a glucuronide is only ef-
fective inside the cell, such studies may not be pos-
sible since most likely the glucuronides will be
taken up only slightly by cells due to the poor lipid
solubility of these compounds. Only uptake in hepa-
tocytes may be efficient, as shown by the fact that
glucuronides are in general rapidly excreted in bile
in many species after intravenous administration
(14). Hydrolysis of glucuronides usually does not oc-
cur in the body when they are injected intravenous-
ly (15).
Dietary Methods to Decrease
Sulfate Availability
It would appear to be relatively easy to decrease
sulfation by a reduction of sulfate availability by al-
teration of the diet. However, it turns out that this
is more complicated than it looks at first sight. First
of all, during fasting for several days, serum sulfate
does not decrease, presumably because enough sul-
fate is provided by catabolism of cysteine, which is
not required for protein synthesis, to inorganic sul-
fate (16). Only the amount of sulfate excreted in
urine decreases under those conditions, which indi-
cates that the rate at which sulfate becomes avail-
able in the body has been lowered considerably.
Surprisingly, the steady-state rates of glucuroni-
dation and sulfation of a phenolic substrate, harmol,
were almost unaffected in rats fasted for 3 days (17).
Feeding a diet that is low in sulfur-containing
amino acids similarly has little effect on serum sul-
fate (Table 1). The reason may be that at very low
methionine (and no cysteine) in the food, growth
stops and a catabolic state, comparable to fasting,
follows; indeed, the urinary excretion of sulfate had
been reduced by more than 50% (Mulder and Glaz-
enburg, unpublished data).
The only diet that was highly effective in decreas-
ing serum sulfate was an 8% (w/v) casein diet that,
after 4 days, reduced the serum sulfate concentra-
tion in rats from the normal value of approx. 0.9
mM to 0.1-0.3 mM. This indicates a very effective
decrease in sulfate availability. The first few days
on this diet the rats lose some weight, but after 3
days they resume growth. When sulfate is infused
intravenously in these animals, they still are
capable of conjugation with sulfate and glucuron-
ate at normal rates after 4 days on this diet. There-
fore, the conjugating systems are completely unaf-
fected under these conditions (apart from the cofac-
tor availability).
Additional sulfate or the sulfate precursor L-
cysteine added to the food had little effect on serum
sulfate in rats (Table 1): the amount absorbed from
the gut is eliminated continuously by the kidneys,
so that no increased serum sulfate concentration
results (16). Of course, if much of the endogenous
sulfate is consumed by sulfation of a substrate, addi-
tional sulfate (or cysteine) in the food would
replenish this loss of sulfate.
Sulfate required for N,O-sulfonation is not elimi-
Table 1. Effect of dietary changes on sulfate availability in the rat in vivo.
Urinary sulfate
Diet Serum sulfate, mM Mmole/24 hr/kg Reference
Control 0.85 - 1.0 1800- 2000 (20)
8% Casein (for 4 days) 0.1 - 0.3 150 - 200 (16)
Synthetica b
100 Cys/100 Met 1.07 1900
25 Cys/ 25 Met 1.20 800
0 Cys/ 25 Met 1.20 650
25 Cys/ 25 Met
+ 150 sulfate 1.10 6000
Fasting (for 3 days) 0.94 1000 (16)
aThe diet consisted of pure amino acids, peanut oil, corn starch, vitamins and minerals; the composition is almost identical to that
reported elsewhere. (18). 100 Met means 22 mmole L-methionine per kg of the diet; 100 Cys means 26 mmole L-cysteine/kg food;
150 sulfate means 36 mmole sodium sulfate/kg food. These diets were given 8 consecutive days.
bData of Glazenburg et al., in preparation.
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nated from the body because the conjugates break
down rapidly, inside the cell, and return the sulfate
group back to the cellular sulfate pool. Only when a
high dose of cysteine or sulfate is given orally as a
single dose does serum sulfate increase for a pro-
longed period of time (16, 19, 20).
In conclusion, sulfate availability can be de-
creased by feeding rats an 8% casein diet, and it
can only be increased when high doses of sulfate or
cysteine are given acutely.
Acetaminophen Pretreatment to
Decrease Sulfate Availability
In Vivo
Many substrates of sulfation can deplete sulfate
in the body when they are given in high doses, for
instance, salicylamide, acetaminophen (paracetamol)
and harmol (21-23). Several investigators in the field
of aromatic amine carcinogenesis have employed ac-
etaminophen to elucidate the role of sulfation in the
generation of ultimate carcinogenic metabolites (24-
27). The idea was that acetaminophen would deplete
sulfate selectively and thereby decrease sulfation of,
for instance, N-hydroxy-2-AAF. Adding inorganic
sulfate or cysteine to the food would restore sulfate
availability to the normal level. However, while
high doses of acetaminophen do cause a decrease in
serum sulfate, there is also much unconjugated
acetaminophen present at the same time (16, 23). It
has been shown by various groups that acetamino-
phen may have many other effects besides decreas-
ing sulfate (27), such as an inhibition of transacetyl-
ation of N-hydroxy-2-AAF (28). Therefore, this is
certainly not a method of choice, and results from
these types of experiments should be analyzed with
much caution.
Moreover, the addition of sodium sulfate or cyste-
ine to the diet did not result in a rise in the plasma
sulfate concentration in the rat (19), although it may
restore the sulfate levels to normal in acetamino-
phen-pretreated rats.
Selective Inhibition of Sulfation by
Pentachlorophenol (PCP) and 2,6-
Dichloro-4-Nitrophenol (DCNP)
In 1977 two selective inhibitors of sulfation were
discovered that had no effect on glucuronidation:
pentachlorophenol (PCP) and 2,6-dichloro4-nitro-
phenol (DCNP) (29). PCP strongly inhibited the in
vitro sulfation of N-hydroxyphenacetin and N-hy-
droxy-2-AAF, while DCNP was less effective (29, 30).
The mechanism is reversible competitive inhibition
with respect to the acceptor substrate (31, 32). The
inhibition of sulfation by these compounds has re-
cently been reviewed. (33).
Pure PCP has relatively low toxicity (34), apart
from its strong uncoupling action on oxidative phos-
phorylation. However, in the rat in vivo the inhibi-
tion of sulfation seems to occur at PCP concentra-
tions that do not yet affect oxidative phos-
phorylation. Since PCP has a rather long half-life (6-
24 hr) (34, 35), it seems a promising drug for use in
studies on the role of sulfation in carcinogenesis by
aromatic amines. It can be administered with the
food or dissolved (as sodium salt) in the drinking
water. If it is given for a prolonged period of time at
1.4 mM in the drinking water, the plasma levels of
PCP are approximately 100 ,m. Alternatively, it
can be given as a single intraperitoneal injection or
as sodium salt in osmotic micropumps that can be
implanted subcutaneously. Very high infusion rates
can be given by a single osmotic minipump during
two weeks: 90 Hmole/hr, also resulting in a plasma
concentration of 100 M (35). Therefore, it is rela-
tively easy to ensure a high plasma level of PCP for
a prolonged period of time as required in experi-
ments in which sulfation has to be inhibited for
several weeks.
PCP pretreatment resulted in pronounced
changes in the metabolism ofN-hydroxy-2-AAF and
the related hydroxamic acid N-hydroxy4'-fluoro-4-
acetylaminobiphenyl (N-hydroxy-FAAB) (30, 36). As
shown in Table 2, the formation of the N,O-glucuro-
nide conjugates was greatly increased. Although
the eventually formed N,O-sulfonates could not be
measured directly because of their extreme lability,
the above findings seemed to suggest that sulfation
of the hydroxamic acids at the N-hydroxy group is
inhibited, and that a compensatory increase in glu-
curonidation has occurred (30,36). Indeed, when the
metabolism ofN-hydroxy-2-AAF was determined in
the isolated perfused rat liver, the omission of sul-
fate from the perfusion medium resulted in a simi-
lar, pronounced increase of theN,O-glucuronide pro-
duction, which could not further be increased by the
Table 2. Effect of PCP and DCNP pretreatment on the
formation of theN,O0iglucuronide from N-hydroxy-2-AAF and
N-hydroxy-FAAB in the rat in vivo.a
Percentage of dose excreted in
bile and urine as the
N,O-glucuronide
Substrate Control PCP DCNP
N-Hydroxy-2-AAF 26.5 + 1.6 47.4 ± 1.9 N.D.
N-Hydroxy-FAAB 18.0 ± 0.4 39.4 ± 0.8 23.8 ± 1.7
aThe dose of both substrates was 60 *mole/kg (IV); bile and
urine were collected for 4 hr after injection (30, 36). The
rats were pretreated 45 min before the injection of the
substrate with PCP or DCNP (or the solvent in controls) at
40 Amole/kg (I.P.). The mean for four rats ± SEM are given;
N.D. means not determined.
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addition of PCP to the perfusion medium (30). If,
therefore, the increase in the N,O-glucuronide conju-
gate excreted above the control level in the pres-
ence of PCP was taken to be due to the inhibition of
N,O-sulfonation, approximately 20-40% of the dose
ofN-hydroxy-2-AAF employed in the study of Meer-
man et al. (30) was converted to the reactive N,O-
sulfonate conjugate. For N-hydroxy-FAAB this was
ca. 20% (36).
Another indication of the generation of reactive
intermediates can be gained from the amount of the
substrate that becomes covalently bound to protein,
RNA and DNA. It should be realized that sulfation
is not the only pathway to form a reactive interme-
diate from hydroxamic acids, since deacetylation
and transacetylation may also yield reactive species.
Pentachlorophenol inhibited the covalent binding of
N-hydroxy-2-AAF andN-hydroxy-FAAB to the total
macromolecular fraction of the liver (30, 36). For
N-hydroxy-FAAB the same was found for the
kidney, also a target organ for carcinogenesis by
this compound but in the spleen (not a target organ)
PCP had no effect on covalent binding (Table 3).
Table 3. Effect of PCP and DCNP on covalent binding of
[9-'4C]-N-hydroxy-2-AAF and [ring_3H]-N-hydroxy-FAAB
to macromolecules in the liver, kidney and spleen of the rat.a
Binding, pmole/mg
Control PCP DCNP
N-Hydroxy-2-AAF
Liver DNA 162 ± 20 132 ± 12 103 ± 4
Liver RNA 301 ± 27 120 ± 7 155 ± 12
Liver protein 472 ± 42 168 ± 32 224 ± 55
N-Hydroxy-FAAB
Liver 530 ± 31 290 ± 29 505 ± 32
Kidney 897 ± 28 561 ± 67 931 ± 84
Spleen 179 ± 48 202 ± 21 N.D.
aThe dose and pretreatments were as in Table 2. Means ±
S.E.M. are given; N.D. means not determined. For covalent
binding to DNA and RNA, the binding as pmole/mg DNA
and RNA is given; for covalent binding to protein and total
covalent binding to all macromolecules (for N-hydroxy-
FAAB) it is expressed per milligram protein (30, 36).
Further work with N-hydroxy-2-AAF showed
that PCP prevented primarily covalent binding of
[9-14C]-labeled N-hydroxy-2-AAF to protein, which
accounts for most of the covalent binding in the
liver. However, binding to DNA was also decreased
(Table 3). Later (37) it was shown that the DNA ad-
ducts which retained their N-acetyl group were de-
creased selectively by PCP, while the deacetylated
adducts were unaffected (Table 4). Since sulfation
leads only to adducts that retain their N-acetyl
group this PCP effect seems to indicate that the
Table 4. Effect of PCP pretreatment on the formation of
various DNA adducts to guanine fromN-hydroxy-2-AAF
in rat liver DNA.a
Adducts, pmole in the butanol extract
Adduct to of 1 mg hydrolyzed DNA
guanine Controls PCP-treated
N-Acetylated adducts
N2- AAF 2.7 ± 0.4 1.4 ± 0.1
C8 - AAF 23.7 ± 4.1 6.6 ± 0.7
De-acetylated adducts
C8 - AF 40.1 ± 6.2 53.0 ± 3.8
aRats were pretreated with PCP (40 Mmole/kg, IP) or with
solvent; 45 min later they received an injection (IV) of 60
,mole/kg [ring-3H] N-hydroxy-2-AAF. Means ± S.E.M. are
given for four or five rats. N2 and C8 indicate adducts
through the N2 and C8 of guanosine, respectively (37).
greater part of these adducts are formed by sulfa-
tion (37).
Another property ofN-hydroxy-2-AAF is its hepa-
totoxicity. Specifically the periportal, "zone 1" cells
are damaged (38, 39), and lymphocyte infiltration in
this area is observed after 1 day. Both PCP and
DCNP prevented this effect of N-hydroxy-2-AAF
very effectively (39), indicating that this effect is
related to the sulfation ofN-hydroxy-2-AAF. The re-
lease of transaminases from the liver after N-hy-
droxy-2-AAF and its prevention by PCP and DCNP
confirmed the protective effect of the latter com-
pounds (39). It remains to be seen whether or not
the cytotoxic effect is somehow involved in promo-
tion of the carcinogenic action of2-AAF.
Study of the Role of Sulfation in
Isolated Systems
Although it is difficult to evaluate the role of sul-
fation in the generation of unstable, reactive inter-
mediates in vivo, it is easier in isolated systems
such as the perfused liver or isolated hepatocytes.
These can be perfused or incubated in the absence
of inorganic sulfate so that the only source of sulfate
is that which is available in the liver. It should be
realized that the liver can generate its own sulfate
from sulfoxidation of cysteine or from breakdown of
sulfated macromolecules such as glycosaminogly-
cans. Therefore, sulfation will certainly continue at
a low rate even when inorganic sulfate and the sul-
fur-containing amino acids are completely deleted
from the system.
Sometimes even the results with such systems
are still hard to explain. For example, omission of
sulfate from the incubation medium decreased
covalent binding of N-hydroxy-2-AAF to protein
(40), but had no effect whatsoever on covalent bind-
ing of 2-AAF (41).
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Role of Glutathione in
Detoxication of the Reactive
Intermediates Generated from
Acetylaminofluorene
When the sulfate conjugate of N-hydroxy-2-AAF
breaks down, it generates an electrophilic AAF de-
rivative that can bind not only to nucleophilic
groups in protein, RNA or DNA, but also to the -SH
group of glutathione. The chemical reaction be-
tween N-acetoxy-2-AAF and glutathione in vitro
yields four glutathione conjugates, at the 1-, 3-, 4-
and 7- positions of the fluorene ring (42). All of these
retained the N-acetyl group. Glutathione conjugates
without this N-acetyl group are formed if, for in-
stance, nitrosofluorene is reacted in vitro with glu-
tathione (43). In the rat, in vivo, the 1- and 3-gluta-
thion-S-yl-AAF conjugates are formed from N-hy-
droxy-2-AAF. There was no evidence in preliminary
experiments for the formation in vivo of deacety-
lated glutathione conjugates (Meerman, Kadlubar
and Mulder, unpublished results). PCP pretreat-
ment decreased the formation of both glutathione
conjugates from N-hydroxy-2-AAF in vivo consider-
ably, indicating that a major part of these conju-
gates had been formed through sulfation.
Similar glutathione conjugates resulted from the
spontaneous breakdown of the N,O-glucuronide con-
jugate ofN-hydroxy phenacetin (5).
As yet it is unclear why glutathione, while still
available, cannot detoxify all of the reactive inter-
mediate formed from N-hydroxy-2-AAF in vivo, so
that much becomes covalently bound to protein and
DNA, whereas glutathione protects completely
against paracetamol toxicity. Some reasons for this
have been discussed elsewhere (44).
Sulfation of Hydroxamic Acids:
Initiation or Promotion?
It has been suggested that sulfation of
N-hydroxy-2-AAF is not responsible for initiation,
but for tumor promotion, while initiation may be
due to a different metabolite of N-hydroxy-2-AAF
(45,46). This promotion might be related to the hepa-
totoxic action that is the consequence of sulfation
ofN-hydroxy-2-AAF (44), which leads to a regenera-
tive growth of the liver. To study this, the inhibi-
tory action of PCP on sulfation can very convenient-
ly be used in various test systems to further ana-
lyze the role of sulfation in initiation and promotion
by AAF. Results of these types of experiments will
become available in due time.
The research from our own laboratory has been supported
by a grant from the Dutch Cancer Foundation (Koningin
Wilhelmina Fonds).
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